FGFR as a Biomarker: Diagnostic, Prognostic, and Therapeutic Perspectives

This webinar from the Association for Molecular Pathology will discuss FGFR family alterations as biomarkers across solid tumors, covering the spectrum of alteration types as well as key examples including urothelial carcinoma, cholangiocarcinoma, gastric adenocarcinoma, and thyroid carcinoma, to illustrate diagnostic, prognostic, and predictive/therapeutic roles. An emphasis will be placed on how the same gene family can carry different clinical significance depending on tumor context, alteration type, and testing modality.